Relative contribution of risk factors/co-morbidities to heart failure pathogenesis: interaction with ejection fraction

被引:5
|
作者
Giamouzis, Grigorios [1 ]
Xanthopoulos, Andrew [1 ]
Papamichalis, Michail [1 ]
Chroub-Papavaiou, Artemis-Nantia [1 ,2 ]
Pantziou, Aikaterini [1 ,3 ]
Simou, Anthi [1 ]
Dimos, Apostolos [1 ]
Bourazana, Angeliki [1 ]
Skoularigis, John [1 ]
Triposkiadis, Filippos [1 ]
机构
[1] Gen Univ Hosp Larissa, Dept Cardiol, POB 1425, Larisa 41110, Greece
[2] Papageorgiou Gen Univ Hosp, Thessaloniki, Greece
[3] Gen Hosp Volos, Dept Cardiol, Volos, Greece
来源
ESC HEART FAILURE | 2020年 / 7卷 / 06期
关键词
Heart Failure; Morbidity; Co-morbidity; Coexisting disease; Hypertension; Myocardial infarction; Atrial fibrillation; Ejection fraction; NONCARDIAC COMORBIDITIES; CO-MORBIDITIES;
D O I
10.1002/ehf2.12975
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Aims The relative impact of each individual coexisting morbidity on the pathogenesis of heart failure (HF) is incompletely understood. This study aimed to evaluate the prevalence of individual cardiac and non-cardiac coexisting morbidities both in the overall HF population and in the subgroup of HF patients with a single coexisting morbidity, stratified by left ventricular ejection fraction (LVEF) categories, as a measure of the relative contribution of each co-morbidity to the pathogenesis of HF. Methods and results This is a prospective, observational study, in which unselected ambulatory patients with chronic HF visiting the HF clinic of a tertiary university hospital from January 2016 to January 2019 were classified according to baseline LVEF into three groups: (i) LVEF < 40%, (ii) LVEF = 40-49%, and (iii) LVEF >= 50% and then evaluated for various coexisting morbidities. Overall, 1064 patients (age 73.4 +/- 12.1 years, male gender 57.7%, LVEF 43.6 +/- 13.9, N-terminal pro-brain natriuretic peptide 2187 +/- 710 ng/L, and estimated glomerular filtration rate 67.2 +/- 25 mL/min/1.73 m(2)) were recruited in this study. Of these, 361 (33.9%) had an LVEF < 40%, 247 (23.2%) an LVEF = 40-49%, and 456 (42.9%) an LVEF >= 50%. There were 90 (8.5%) HF patients with a single coexisting morbidity, 33 (36.7%) with LVEF >= 50%, 27 (30.0%) with LVEF = 40-49%, and 30 (33.3%) with LVEF < 40%. Among these patients, those with LVEF >= 50% suffered mostly from hypertension (85.7%), whereas the second most common coexisting morbidity was atrial fibrillation (AF) (9.5%). HF patients with LVEF = 40-49% usually suffered from hypertension (35.7%), AF (28.6%), or myocardial infarction (MI) (21.4%). Finally, HF patients with LVEF < 40% usually suffered from MI (30.8%), AF (30.8%), or hypertension (15.4%). Conclusions Hypertension is strongly associated with the development of HF with low, intermediate, or near-normal/normal LVEF whereas a history of MI or AF with HF with a low or an intermediate LVEF.
引用
收藏
页码:4399 / 4403
页数:5
相关论文
共 50 条
  • [1] Complexities of treating co-morbidities in heart failure with preserved ejection fraction
    Zlahtic, Tadej
    Mrak, Miha
    Zizek, David
    ESC HEART FAILURE, 2024, 11 (05): : 2481 - +
  • [2] Biomarkers, myocardial fibrosis and co-morbidities in heart failure with preserved ejection fraction: an overview
    Michalska-Kasiczak, Marta
    Bielecka-Dabrowa, Agata
    von Haehling, Stephan
    Anker, Stefan D.
    Rysz, Jacek
    Banach, Maciej
    ARCHIVES OF MEDICAL SCIENCE, 2018, 14 (04) : 890 - 909
  • [3] Heart failure ejection fraction class conversions: impact of biomarkers, co-morbidities, and pharmacotherapy
    Lorenzo, Christian J.
    Conte, Jorge, I
    Villasmil, Ricardo J.
    Abdelal, Qassem K.
    Pierce, Derek
    Wiese-Rometsch, Wilhelmine
    Garcia-Fernandez, Joel A.
    ESC HEART FAILURE, 2022, 9 (04): : 2538 - 2547
  • [4] The Prevelence of Common Co-Morbidities Impacts the Pathophsyiology of Patients with Heart Failure and Normal Ejection Fraction
    Abramov, Dmitry
    Maurer, Mathew S.
    Burkhoff, Daniel
    Wang, Jie
    He, Kun-Lun
    JOURNAL OF CARDIAC FAILURE, 2009, 15 (06) : S24 - S24
  • [5] Co-morbidities and fragility are determinants of survival in patients with heart failure and mildly reduced ejection fraction
    Moliner, P.
    Gastelurrutia, P.
    Lupon, J.
    Yang, X.
    De Antonio, M.
    Domingo, M.
    Altimir, S.
    Gonzalez, B.
    Rodriguez, M.
    Rivas, C.
    Fung, E.
    Zamora, E.
    Santesmases, J.
    Woo, J.
    Bayes-Genis, A.
    EUROPEAN JOURNAL OF HEART FAILURE, 2017, 19 : 452 - 452
  • [6] Frailty, co-morbidities and survival in heart failure patients with mid-range ejection fraction
    Moliner, P.
    Gastelurrutia, P.
    Lupon, J.
    Yang, X.
    De Antonio, M.
    Domingo, M.
    Altimir, S.
    Gonzalez, B.
    Rodriguez, M.
    Rivas, C.
    Fung, E.
    Zamora, E.
    Santesmases, J.
    Woo, J.
    Bayes-Genis, A.
    EUROPEAN HEART JOURNAL, 2017, 38 : 111 - 111
  • [7] Co-morbidities in heart failure
    van Deursen, Vincent M.
    Damman, Kevin
    van der Meer, Peter
    Wijkstra, Peter J.
    Luijckx, Gert-Jan
    van Beek, Andre
    van Veldhuisen, Dirk J.
    Voors, Adriaan A.
    HEART FAILURE REVIEWS, 2014, 19 (02) : 163 - 172
  • [8] Co-morbidities in heart failure
    Vincent M. van Deursen
    Kevin Damman
    Peter van der Meer
    Peter J. Wijkstra
    Gert-Jan Luijckx
    Andre van Beek
    Dirk J. van Veldhuisen
    Adriaan A. Voors
    Heart Failure Reviews, 2014, 19 : 163 - 172
  • [9] September 2018 at a glance: co-morbidities, heart failure with preserved ejection fraction and mineralocorticoid receptor antagonists
    Metra, Marco
    EUROPEAN JOURNAL OF HEART FAILURE, 2018, 20 (09) : 1245 - 1246
  • [10] Co-morbidities in Heart Failure Preface
    Zannad, Faiez
    Ventura, Hector O.
    HEART FAILURE CLINICS, 2014, 10 (02) : XI - XI